skeleton, as also suggested by the anatomical-mechanical theory. 12 Upon invading and transversing the bone marrow cavity, the primary tumor cells can alter the bone remodeling process by increasing the rates of osteoblast and osteoclast activity. 13 The severity of the pathologically increased bone remodeling initiated by metastatic CRPC is evident from the high serum levels of both bone-forming and -degrading biochemical markers when compared to patients with bone metastases from other solid tumors. 14, 15 The increased activity of the osteoblasts and osteoclasts leads to a degradation of the quality of bone as weaker, sclerotic bone replaces normal trabecular bone. In addition, the homeostasis mechanism of remodeling uncouples as bone breakdown outpaces bone formation, resulting in a net loss of bone. Collectively, the formation of weaker bone architecture and localized loss of bone mass leads to a net loss of skeletal strength (compressive and bending forces), which may lead to an increase in SRE rates. 16 
Bone Turnover Markers
Biochemical markers of bone metabolism, both formation and resorption, can provide valuable insight into the impact of therapies and tumor and bone interactions. 17 Although there is still debate on their prognostic and predictive value in diagnosing bone metastases, bone turnover markers have been shown to indirectly measure the treatment effects for bone metastases in prostate cancer patients. 15 Urinary NTx (uNTx), a breakdown product of N-telopeptide (bone, type-1 collagen), and serum tartrate-resistant acid phosphatase 5b (TRAP 5b) are the primary biomarkers associated with bone resorption and disease progression. Bone-specific alkaline phosphatase (BAP), a measure of osteoblastic activity, is also considered a prognostic indicator in patients with CRPC. 15, 18, 19 Studies have demonstrated that elevated levels of uNTx indicate excessive bone resorption and can be predictive of SREs and progression of bone lesions across a wide range of tumor types. 20, 21 Cancer patients receiving bisphosphonate therapy while continuing to have elevated uNTx levels ([moderate = 50-99 nmol/mmol creatinine] or [high = >100 nmol/mmol creatinine]), had a significantly increased risk for adverse outcomes such as SREs and death compared to patients with low values (<50 nmol/mmol creatinine) uNTx.
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Clinical Manifestation
The median overall survival for men with advanced prostate cancer and bone metastases has been reported to be up to two years. 22 Without bone-specific therapeutic intervention, progression of CRPC with bone metastases can lead to SREs such as pathologic fractures, spinal cord compression, and surgery or radiation to the bone. 23 More than half of all men with prostate cancer and bone metastases will experience an SRE in their lifetime and the median time to first SRE has been reported as short as 10.7 months (see Figure 1) . 24 The mean incidence rate of SREs has been reported as 1.47 events per year in cancer patients with bone metastasis. 25 With the recent discovery of effective systemic therapies, the progression of prostate cancer can be slowed allowing for improved survival rates.
However, the probability of a potentially debilitating SRE also increases with the prolongation of survival. Prior studies in men with prostate cancer suggest that pathologic fractures can occur at any skeletal site and are associated with significant decreases in functional and psychological well being. 27 Bone pain, a common consequence of bone metastases, 
Bisphosphonates
Bisphosphonates are a class of pharmacologic agents used for the treatment of bone diseases associated with excessive bone resorption.
Structurally, they are analogs of inorganic pyrophosphate and interfere with osteoclast metabolism and survival. 34 The first generation of bisphosphonates (non-nitrogen) included etidronate, clodronate, and tiludronate are able to induce osteoclast apoptosis by metabolism into cytotoxic analogs of adenosine 5'-triphosphates. 35 The primary mechanism of action of the newer nitrogen-containing compounds; alendronate, ibandronate, pamidronate, risedronate, and zoledronic acid, is through the inhibition of farnesyl diphosphate synthase which in turn suppresses osteoclast mediated bone resorption. 34 In 1995, pamidronate gained US Food and Drug Administration (FDA)
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approval for the prevention of SREs in patients with bone metastases due to breast cancer or bone disease from advanced multiple myeloma. 36, 37 However, in randomized, controlled trials of men with prostate cancer and bone metastases, both pamidronate and clodronate failed to demonstrate long-term risk reductions for SREs versus placebo. [38] [39] [40] In a later study, a more efficacious bisphosphonate, zoledronic acid (Zometa ® 704 trial)
was also compared with placebo for the time to development of first bone metastases. 41 Although terminated, analysis of the partial cohorts revealed no significant difference in time to first bone metastasis. In 2002, after completion of three large, Phase 3 trials, intravenous (IV) zoledronic acid was approved for the prevention of disease-related skeletal complications in patients with bone disease from myeloma or bone metastases from prostate, breast, or lung cancer. [42] [43] [44] In these trials, IV zoledronic acid reduced the number of SREs compared with placebo in CRPC patients with bone metastases.
Denosumab
Denosumab is a fully human, IgG2 monoclonal antibody designed to target the bone remodeling system and inhibit bone destruction by binding RANKL with high specificity and affinity (Kd = 3x10 -12 ). 45 It binds to both soluble and membrane-bound RANKL and does not cross-react with other TNF ligand family members. Similar to osteoprotegerin (OPG), denosumab is a reversible antagonist of RANKL that interferes with RANKL and RANK interactions. In the late 1990s, elucidation of the RANKL, RANK, and osteoprotegerin (OPG) pathway revealed a central molecular paradigm in osteoclast functionality which provided key insights to the basic mechanism of bone remodeling. 46, 47 The reciprocal interactions between RANKL and the RANK receptor are central for the regulation of bone osteoclast-mediated resorption, which in turn mediates bone remodeling under both normal and pathological conditions. OPG, a member of the TNFR family, was shown to bind RANKL and behave as a type of decoy receptor for RANKL. 48, 49 The key role of OPG in bone remodeling was demonstrated in transgenic mice overexpressing OPG, 50 where the reduction in the number of osteoclasts led to osteopetrosis and conversely, osteopenia in OPG knockout mice. 51 These observations led to the hypothesis that the bone microenvironment and interplay of RANK, RANKL, and OPG are critical for osteoclastogenesis and homeostatic bone remodeling, thus providing the clinical rationale to pursue RANKL as a key pharmaceutical target to curb aberrant bone remodeling in human cancers and bone metastases.
To evaluate the pharmocodynamics of denosumab-induced RANKL inhibition in humans, a randomized, double-blind, double-dummy, active-controlled Phase 1 study was conducted in patients with metastatic breast cancer and multiple myeloma. 52 In this study, patients with bone lesions due to breast cancer or myeloma received either denosumab as a single, SC injection or IV pamidronate. Denosumab suppressed the bone turnover marker uNTx through 84 days and demonstrated a half-life of approximately one month. The magnitude of uNTx suppression was similar to IV pamidronate but was considerably more sustained. 52 In a Phase 2 study of women with breast cancer and bone metastases, treatment with either denosumab or IV bisphosphonates suppressed uNTx levels in the first week of treatment. 53 By the end of the 13-week study, decreases in the bone turnover markers were comparable between denosumab and bisphosphonate treated patients.
Equally important, denosumab reported a reduced incidence of first on-study SREs compared to bisphosphonates; 9 % for denosumab versus 16 for IV bisphosphonate-patients. 53 A second Phase 2 study examined the effects of denosumab or bisphosphonate therapies in cancer patients with bone metastases and elevated uNTx levels despite prior bisphosphonate therapy. The primary endpoint of lower uNTx levels (<50) at week 13 was achieved by 71 % of patients receiving denosumab compared to 29 % of patients continuing bisphosphonates, p<0.001.
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The lower uNTx levels were sustained at week 25, 64 % for the denosumab arm versus 37 % for the bisphosphonate arm, p<0.01. Similar to an earlier Phase 2 study, reported SRE rates were lower for denosumab-(8 %) versus bisphosphonate-(17 %) treated patients.
Recently, the results of a large Phase 3 trial comparing denosumab with zoledronic acid in bisphosphonate-naive patients with advanced CRPC and bone metastases were reported. 55 The trial was a randomized, double-blind, double-dummy, active comparison of SC denosumab (120 mg) or IV zoledronic acid (4 mg, adjusted for creatinine clearance) every four weeks. A total of 1,904 patients were randomized, of whom 1,901 were eligible for the efficacy analysis: 950 were assigned to denosumab and 951 were assigned to zoledronic acid. The primary endpoint was time to first on-study SRE and was defined as a pathological fracture, radiation therapy, surgery to the bone, or spinal cord compression.
In the efficacy analysis, denosumab demonstrated superiority to zoledronic acid for the delay or prevention of SREs in patients with advanced prostate cancer and significantly delayed time to first on-study SRE by 18 % (p=0.008 for superiority analysis) (see Figure 2 ). Time to first and subsequent SRE was also significantly delayed (p=0.008) compared to zoledronic acid (see Figure 3) .
These results established that denosumab was more efficacious than the prior standard of care, zoledronic acid, for the delay or prevention of SREs in patients with advanced prostate cancer. Decreases in the bone turnover markers of uNTx and BSAP were significantly greater with denosumab versus zoledronic acid (p<0.0001) by week 13, mirroring the reduction in SREs. For both groups, the median overall survival of 20 months was expected for the study population and not different between the treatment groups. Reported disease progression was not comparably different between the treatment groups.
Safety
In the reported Phase 3 trial of denosumab versus zoledronic acid in men with advanced CRPC with bone metastases, the overall occurrences of adverse events (AEs) and serious adverse events (SAEs) were similar between the two arms, including the two-year cumulative incidence of ONJ (2 % denosumab, 1 % zoledronic acid) and renal impairment (15 % denosumab, 16 % zoledronic acid). 55 Unexpected changes in serum
creatinine levels, were not observed in the denosumab arm. A greater incidence of hypocalcemia was reported in the denosumab arm (13 % denosumab, 6 % zoledronic acid). Hypocalcemia is an expected risk with potent anti-resorptive therapies and forms the basis for the clinical recommendation that all patients receive supplemental calcium and vitamin D. Neutralizing antibodies to denosumab were not detected in any patients tested in the clinical studies. 56 Reported deaths were attributable to cancer or its complications and none were considered related to denosumab or zoledronic acid. 57 Unlike IV zoledronic acid, the AEs associated with acute phase reactions (APRs) (within three days after treatment) were significantly lower for denosumab arm (8 %) than for zoledronic acid arm (18 %). The increased incidence of reported there were no benefits in the prevention of bone metastases. In a follow-on study, zoledronic acid (Zometa ® 704 trial) was compared with placebo for time to development of first bone metastases in non-metastatic CRPC. The trial was delayed and eventually discontinued because of a low event rate. However, analysis of the partial cohorts of zoledronic acid and placebo revealed no significant differences in the time-to-first metastases. 66 Recently, a Phase 3 study evaluating the effects of altering the bone microenvironment utilizing denosumab was conducted in CRPC patients without bone metastases but at high risk for bone metastases. 67 Eligible patients were randomized to either denosumab (716 patients) or placebo (716 patient) and were stratified by PSA eligibility criteria and previous or ongoing chemotherapy for prostate cancer. The primary endpoint was bone metastasis-free survival which was a composite endpoint determined by time-to-first occurrence of either asymptomatic or symptomatic bone metastases or death of any cause. Denosumab significantly increased bone metastasis-free survival by a median of 4.2 months compared with placebo (p=0.028) and also delayed time to first bone metastasis (33.2 months versus 29.5 months, p=0.032).
Emerging Therapies
Until recently, bone treatment options for patients with CRPC were limited.
With the advancements in understanding of tumor derived factors, host factors, and bone microenvironments, emerging cancer therapeutics have targeted hormonal signaling pathways, bone derived factors, cell-cycle checkpoints, and activated tyrosine kinases. 
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SRC inhibitor
The proto-oncogene tyrosine kinase SRC has established roles in pathogenesis of visceral and bone metastases 70, 71 and regulation of normal osteoclast function. [72] [73] [74] Dasatinib, a potent SRC inhibitor with pre-clinical antineoclast and antitumor activity, has demonstrated inhibitory activity against bone regulatory mechanisms including osteoclastogenesis, prostate cancer cell-induced osteoclast differentiation and activity, and osteoblast proliferation. [75] [76] [77] [78] In a Phase 2 trial in patients with chemotherapy-naive CRPC and increasing PSA levels, single agent dasatinib (100 mg, once daily) decreased uNTx levels (51 % patients had a >40 % decrease) and BAP levels (59 % of patients) in the majority of patients. The most common treatment associated adverse event were fatigue, nausea, and diarrhea while 13 % of the patients had grade 3 to 4 side effects. 
